Stop parsing PDFs. Get the API. Request Access
Editas Medicine, Inc. Logo

Editas Medicine, Inc.

A clinical-stage genome editing company developing CRISPR medicines for serious diseases.

EDIT | US

Overview

Corporate Details

ISIN(s):
US28106W1036
LEI:
Country:
United States of America
Address:
11 HURLEY ST., 2141 CAMBRIDGE
Website:
https://www.editasmedicine.com/
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Editas Medicine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Editas Medicine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Editas Medicine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Circio Holding ASA Logo
Circio Holding ASA
Clinical-stage company developing circular RNA medicines and immunotherapies.
Norway
CRNA
CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo
CIZZLE BIOTECHNOLOGY HOLDINGS PLC
A cancer diagnostics developer creating a blood test for early lung cancer detection.
United Kingdom
CIZ
CJ Bioscience Logo
CJ Bioscience
Develops microbiome therapeutics for oncology and IBD using an AI-powered platform.
South Korea
311690
Climb Bio, Inc. Logo
Climb Bio, Inc.
Clinical-stage biotech developing therapies for immune-mediated diseases.
United States of America
CLYM
CODEXIS, INC. Logo
CODEXIS, INC.
A protein engineering company developing enzymes for therapeutics and life sciences.
United States of America
CDXS
COGNITION THERAPEUTICS INC Logo
COGNITION THERAPEUTICS INC
Clinical-stage company developing oral therapeutics for neurodegenerative disorders.
United States of America
CGTX
Combigene AB Logo
Combigene AB
A gene therapy company focused on neurological disorders and chronic pain.
Sweden
COMBI
Compugen Ltd. Logo
Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
Israel
CGEN
COMPUGEN LTD Logo
COMPUGEN LTD
A clinical-stage company using AI to discover cancer immunotherapy drug targets.
United States of America
CGEN
CORESTEMCHEMON Inc. Logo
CORESTEMCHEMON Inc.
Develops stem cell therapies and provides non-clinical CRO preclinical services.
South Korea
166480

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.